Pfizer Reports Phase 3 LIBRETTO-431 Results for Retevmo in RET Fusion-Positive NSCLC

Pfizer today announced results from the Phase 3 LIBRETTO-431 trial evaluating Retevmo (selpercatinib) versus platinum-based chemotherapy with or without pembrolizumab in patients with previously untreated RET fusion-positive non-small cell lung cancer. The trial met its primary endpoint, demonstrating a significant improvement in progression-free survival with Retevmo. The risk of disease progression or death was reduced by 78% with Retevmo.